Publication at First Faculty of Medicine |
2023
Abstract
Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers and continues to be the leading cause of cancer deaths. In the last two decades, targeted therapies have entered the treatment of locally advanced or metastatic NSCLC, significantly changing the treatment paradigm for this cancer.
Molecularil targeted therapies have led to significant proiongation of overall survival in patients diagnosed with advanced NSCLC. Therapeutically targeted agents are rapidly increasing in number and one of them is already inciuded in the indication for adjuvant therapy after surgery for EGFR-sensitive lung cancer.